Google+ Random Musing of a Doctor: New Research Recommends Early Commencement Of Antiretroviral(ARV) Following Positive HIV Diagnosis expr:class='"loading" + data:blog.mobileClass'> Google+

Random Musing of a Doctor Headline Animator

Friday, February 13, 2015

New Research Recommends Early Commencement Of Antiretroviral(ARV) Following Positive HIV Diagnosis

The timing of the commencement of antiretroviral (ARV) therapy has been described to be crucial in the determination of a patient’s chances of developing AIDS. According to the study, starting treatment within a year of detecting the virus decreases patients’ chances of developing AIDS.The researchers however stated that many people who are infected don’t know it yet.
“Two critically important issues in human immunodeficiency virus (HIV) therapeutics are when to start antiretroviral therapy and how well these medications restore immunity,” writes Dr. Timothy Schacker of the University of Minnesota in a recent issue of JAMA Internal Medicine. He is commenting on a study done by the National Institutes of Health, also published in that issue, that looked at when HIV patients started taking antiretroviral meds, and how that correlated with their immune health later.
According to The Atlantic, researchers studied the data of more than 1,000 patients enrolled
in the U.S. Military HIV Natural History Study between 1986 and 2010. They noted how soon patients started taking antiretrovirals after seroconversion—the point after HIV infection at which antibodies to the virus can be detected in a person’s blood. To measure immune health, the researchers looked at patients’ levels of CD4 T-cells—a kind of white blood cell. When people taking antiretroviral medication see their CD4 counts increase to 500 cells per microliter of blood, that is “typically regarded as optimal immune recovery,” the study says.
But according to the study, in healthy, HIV-negative people, that count is more like 900 cells per microliter. So HIV-positive people whose CD4 counts are higher than 500 but lower than 900 cells per microliter could still have a less-than-ideal immune system and be at increased risk for developing AIDS, even if they’re taking the drugs. So for the purposes of this study, 900 cells per microliter was seen as the ideal target that doctors should shoot for when treating patients using antiretrovirals.
Starting antiretroviral treatment within a year or less of seroconversion was associated with better outcomes for the patients, especially if their CD4 levels were at least 500 cells per microliter when they started treatment. These people had a higher chance of getting to the 900 cells per microliter “normal” level and were subsequently at lower risk of developing AIDS. This wasn’t a guarantee—only about a third of patients who started the medication within a year of seroconversion reached normal CD4 levels.
Early intervention might also be easier said than done. According to the Centers for Disease Control and Prevention, one in five people with HIV in the U.S. don’t know they have it. When the infection is still new, they might not be symptomatic, or they may mistake their symptoms for something else. What’s more, only one in three adults, and one in four children, have access to antiretroviral medications.
“The importance of a public health strategy that includes frequent HIV testing in persons at risk and prompt initiation of [antiretrovirals] after diagnosis is underscored by [these] two findings,” the study reads.

No comments:

Post a Comment